Hanmi Pharm. Co. Ltd. Deal History & Licensing Activity
Hanmi Pharm. Co. Ltd. is a mid-size pharma headquartered in KR. Over the past three years, Hanmi Pharm. Co. Ltd. has been involved in 2 licensing and acquisition transactions, with a primary focus on Other (2 deals). The company currently has 7 active clinical trials, primarily in Cardiovascular.
Deals (12mo)
2
Active Trials
7
Top Modality
Other
Focus Area
Cardiovascular
Hanmi Pharm. Co. Ltd. Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Hanmi Pharm. Co. Ltd. in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| HM17321 | Genentech | Other | Preclinical | license | Aug 24, 2026 |
| Sonefpeglutide (HM15912) | Eli Lilly and Company | Peptides | Phase 2 | license | May 31, 2026 |
Hanmi Pharm. Co. Ltd. Pipeline Focus
Therapeutic areas and modalities where Hanmi Pharm. Co. Ltd. is most active based on deal history and clinical trial data.
Therapeutic Areas
Hanmi Pharm. Co. Ltd. Clinical Pipeline
Hanmi Pharm. Co. Ltd. has 7 active clinical trials across 3 development phases.
4
Not Applicable
1
Phase 4
2
Phase 2
See How Your Asset Matches Hanmi Pharm. Co. Ltd.'s Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Cardiovascular assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Cardiovascular Deal Benchmarks
Market sizing, deal terms, and competitive landscape for cardiovascular
Gastroenterology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for gastroenterology
Other Benchmarks
Upfront, milestone, and royalty benchmarks for other deals
Peptides Benchmarks
Upfront, milestone, and royalty benchmarks for peptides deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 700+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Hanmi Pharm. Co. Ltd. Licensing & Deal Activity
Hanmi Pharm. Co. Ltd. is a mid-size pharma company based in KR that has been actively engaged in licensing transactions across the biopharma landscape. With 2 deals over the past three years, Hanmi Pharm. Co. Ltd. ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Hanmi Pharm. Co. Ltd. include Cardiovascular (2 deals and trials), and Gastroenterology (2 deals and trials). In terms of modality, Hanmi Pharm. Co. Ltd. has shown particular interest in other, peptides.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Hanmi Pharm. Co. Ltd. and 700+ other biopharma companies. Use our Solidus to benchmark your asset against Hanmi Pharm. Co. Ltd.'s historical deal terms, or explore all company profiles to find the best partner match for your pipeline.